• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful Salvage Therapy With a High Dose of Furmonertinib in a Case of Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion.

作者信息

Jiang Weizhen, Sha Min, Chen Cheng

机构信息

Department of Respiratory and Critical Medicine, The First Affiliated Hospital of Soochow University, 899 Pinghai Road, Suzhou, 215000, China.

出版信息

Am J Ther. 2023;30(6):e570-e572. doi: 10.1097/MJT.0000000000001504. Epub 2022 Jul 5.

DOI:10.1097/MJT.0000000000001504
PMID:35482932
Abstract
摘要

相似文献

1
Successful Salvage Therapy With a High Dose of Furmonertinib in a Case of Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion.高剂量伏美替尼成功挽救治疗1例携带EGFR外显子20插入突变的肺腺癌患者
Am J Ther. 2023;30(6):e570-e572. doi: 10.1097/MJT.0000000000001504. Epub 2022 Jul 5.
2
First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review.首例报告：厄洛替尼治疗 EGFR 外显子 20 插入突变阳性晚期肺腺癌患者的疗效：两项病例报告和文献复习
Medicine (Baltimore). 2023 Dec 29;102(52):e36667. doi: 10.1097/MD.0000000000036667.
3
Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.表皮生长因子受体（EGFR）第20外显子插入突变的肺腺癌患者对阿法替尼单药治疗的主要临床反应
Clin Lung Cancer. 2021 Jan;22(1):e112-e115. doi: 10.1016/j.cllc.2020.09.005. Epub 2020 Sep 18.
4
A Case of Novel Inversion Mutation of EGFR Exon 19 Leading to Primary Resistance to EGFR TKIs in Lung Adenocarcinoma.一例表皮生长因子受体（EGFR）第19外显子新型倒位突变导致肺腺癌对EGFR酪氨酸激酶抑制剂原发性耐药的病例
J Thorac Oncol. 2018 Jun;13(6):e97-e101. doi: 10.1016/j.jtho.2017.12.014. Epub 2018 Feb 28.
5
[First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient 
with EGFR Exon 20 Insertion Mutantion].甲磺酸伏美替尼一线治疗表皮生长因子受体第20外显子插入突变的肺腺癌患者
Zhongguo Fei Ai Za Zhi. 2024 Mar 20;27(3):241-244. doi: 10.3779/j.issn.1009-3419.2024.102.11.
6
Primary resistance to gefitinib in a patient with lung adenocarcinoma harboring an EGFR exon 19 L747-A750>P mutation.一名携带EGFR外显子19 L747 - A750>P突变的肺腺癌患者对吉非替尼的原发性耐药。
Lung Cancer. 2020 Oct;148:175-176. doi: 10.1016/j.lungcan.2020.08.013. Epub 2020 Aug 21.
7
A possible EGFR TKIs resistance mechanism of lung adenocarcinoma patients with a novel EGFR exon 20-ins mutation: A case report.具有新型表皮生长因子受体（EGFR）第20外显子插入突变的肺腺癌患者的一种可能的EGFR酪氨酸激酶抑制剂（TKIs）耐药机制：病例报告
Lung Cancer. 2021 Feb;152:193-195. doi: 10.1016/j.lungcan.2020.12.014. Epub 2020 Dec 16.
8
A Case of Advanced Lung Adenocarcinoma Harboring an Epidermal Growth Factor Receptor(EGFR) Exon 20 Insertion, D770_N771insSVD.表皮生长因子受体（EGFR）exon20 插入突变，D770_N771insSVD 型晚期肺腺癌 1 例
Gan To Kagaku Ryoho. 2021 Jun;48(6):845-847.
9
Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.阿法替尼治疗携带外显子 18 delE709_T710insD 突变的肺腺癌的疗效。
Jpn J Clin Oncol. 2019 Aug 1;49(8):786-788. doi: 10.1093/jjco/hyz086.
10
Lung Adenocarcinoma Harboring Triple Rare EGFR Exon 18 Mutations Rapidly Developed Resistance to Multiple Therapies.携带三重罕见表皮生长因子受体（EGFR）第18外显子突变的肺腺癌对多种治疗迅速产生耐药性。
Chemotherapy. 2022;67(4):248-252. doi: 10.1159/000525623. Epub 2022 Jun 28.

引用本文的文献

1
Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells.伏美替尼，一种第三代表皮生长因子受体酪氨酸激酶抑制剂，通过抑制癌细胞中的ABCB1和ABCG2克服多药耐药性。
Int J Mol Sci. 2023 Sep 12;24(18):13972. doi: 10.3390/ijms241813972.
2
Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.靶向“不可成药”蛋白的最新进展：从药物发现到临床试验。
Signal Transduct Target Ther. 2023 Sep 6;8(1):335. doi: 10.1038/s41392-023-01589-z.
3
A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
一项评估 furmonertinib 治疗 EGFR 外显子 20 插入突变非小细胞肺癌患者的疗效和安全性的真实世界研究。
J Cancer Res Clin Oncol. 2023 Aug;149(10):7729-7742. doi: 10.1007/s00432-023-04726-x. Epub 2023 Apr 1.
4
Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report.伏美替尼联合安罗替尼治疗1例表皮生长因子受体第20外显子插入突变肺腺癌患者的持续缓解：病例报告
Front Pharmacol. 2023 Feb 3;14:1053805. doi: 10.3389/fphar.2023.1053805. eCollection 2023.
5
Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, "uncommon-G719X, S768I, L861Q") Among the Third-Generation EGFR TKIs?聚焦伏美替尼（阿弗替尼，AST2818）。第三代EGFR酪氨酸激酶抑制剂中的“瑞士军刀”（19号外显子缺失、L858R、T790M、20号外显子插入、“罕见突变-G719X、S768I、L861Q”）？
Lung Cancer (Auckl). 2022 Oct 25;13:67-73. doi: 10.2147/LCTT.S385437. eCollection 2022.
6
[Consensus on Application of Third-generation EGFR-TKI in EGFR Mutated NSCLC 
(2022 Version)].《第三代表皮生长因子受体酪氨酸激酶抑制剂在表皮生长因子受体突变的非小细胞肺癌中的应用共识（2022年版）》
Zhongguo Fei Ai Za Zhi. 2022 Sep 20;25(9):627-641. doi: 10.3779/j.issn.1009-3419.2022.101.47.
7
"Sandwich" Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients.在高度选择的患者中通过酪氨酸激酶抑制剂与单克隆抗体联合治疗强化表皮生长因子受体（EGFR）阻断的“三明治”策略
Front Oncol. 2022 Jul 8;12:952939. doi: 10.3389/fonc.2022.952939. eCollection 2022.